Four analysts set USD 5.03 target for Outlook Therapeutics stock

Published on 10/27/2026 at 20:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Four analysts set a USD 5.03 target on October 25, 2026. Outlook Therapeutics stock costs EUR 0.47 on October 27, 2026 at 8:46 p.m. CEST.

Analyst target and launch plans

Four analysts supported a USD 5.03 average target on October 25, 2026.
Outlook Therapeutics appointed Greg DiPasquale chief commercial officer on October 9, 2026.
Outlook Therapeutics stock costs EUR 0.47 at Lang & Schwarz on October 27, 2026 at 8:46 p.m. CEST.
The company had USD 127.6 million in market capitalization on October 27, 2026.

OTLK, US69012T3059, Illustration mit AI erstellt.

Four analysts set a USD 5.03 average target for Outlook Therapeutics stock on October 25, 2026, according to Bullstory. On October 9, 2026, Outlook Therapeutics appointed Greg DiPasquale as chief commercial officer to lead the U.S. commercialization of LYTENAVA, according to the company release at Outlook Therapeutics. The stock was trading at EUR 0.47 at Lang & Schwarz on October 27, 2026 at 8:46 p.m. CEST.

Target remains far above Nasdaq price

The USD 5.03 average target stands 867.31 percent above the USD 0.52 Nasdaq price used for the comparison on October 27, 2026. The target is based on four analysts, with three buy ratings and one hold rating listed by Bullstory on October 25, 2026.

That spread reflects a high-risk biotechnology profile rather than a near-term earnings valuation. Outlook Therapeutics is developing and commercializing LYTENAVA, an ophthalmic bevacizumab formulation for wet age-related macular degeneration.

Price position and launch scale

OTLK was last quoted at USD 0.52 on Nasdaq on October 27, 2026 at 3:49 p.m. ET. Its 52-week range was USD 0.16 to USD 2.54, while market capitalization stood at USD 127.6 million on the same date.

The EUR 0.47 Lang & Schwarz quote provides the German-market view after the Xetra reference could not be established. The U.S. listing and Nasdaq ticker are identified in the company's investor materials, while the German quote remains the article's euro price.

Commercial leadership before launch

Outlook Therapeutics said the October 9 appointment added a commercial leader with launch experience involving BEOVU, EYLEA and EYLEA HD. The company profile describes LYTENAVA as FDA-approved in the United States and authorized in the European Union and United Kingdom.

For investors, the key numerical tension is the gap between the USD 0.52 market price and the USD 5.03 analyst average. The company also reported USD 8,700 of revenue and a USD 20.32 million net loss for the quarter ended June 30, 2026.

Comparison with peers

OTLK (Nasdaq, USD): price-to-earnings ratio minus 0.47, market capitalization USD 127.6 million.

Arcturus Therapeutics (Nasdaq, USD): up 13.47 percent, price-to-earnings ratio minus 3.39, market capitalization USD 319.6 million.

BioMarin Pharmaceutical (Nasdaq, USD): down 0.27 percent, price-to-earnings ratio 142.50, market capitalization USD 10.8 billion.

What the figures mean

The current quotation keeps Outlook Therapeutics in a speculative phase: the USD 5.03 consensus target is distant from the USD 0.52 Nasdaq price, while the planned LYTENAVA commercialization gives the company a defined operating milestone.

Outlook Therapeutics was trading at EUR 0.47 at Lang & Schwarz on October 27, 2026 at 8:46 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Outlook Therapeutics stock.